About: Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
Creator	Baric, Ralph Schäfer, Alexandra Ma, J Yount, Boyd Cihlar, Tomas Lu, Xiaotao Gully, Kendra Sheahan, Timothy Dinnon, Kenneth Brown, D Perry, Jason Babusis, Darius Denison, Mark Feng, Joy Murakami, Eisuke Porter, Danielle Agostini, Maria Brown, Ariane Chappell, James Dinnon Iii, Kenneth Graham, Rachel Leist, Sarah Lu, J Pruijssers, Andrea Stevens, Laura Graham, A Pruijssers, A Schäfer, A Stevens, M Agostini, K Babusis, B Bilello, John Denison, R George, A George, Amelia Gralinksi, Lisa Gralinksi, S Hughes, Tia Hughes, X Ma, Bin Martinez, David Martinez, T Org, Ardina Pitts, Jared Pont, Du Pont, Venice Sheahan, M
source	Elsevier; Medline; PMC
abstract	Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 μM). Weaker activity is observed in Vero E6 cells (EC50 = 1.65 μM) due to their low capacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase, of SARS-CoV-2. In mice infected with chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function compared to vehicle treated animals. These data demonstrate that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1016/j.celrep.2020.107940
bibo:pmid	32668216
has license	els-covid
sha1sum (hex)	c7c594390203ea1b999c9da2012c33092d764d46
schema:url	https://doi.org/10.1016/j.celrep.2020.107940
resource representing a document's title	Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
has PubMed Central identifier	PMC7340027
has PubMed identifier	32668216
schema:publication	Cell Rep
resource representing a document's body	covid:c7c594390203ea1b999c9da2012c33092d764d46#body_text
is schema:about of	named entity 'inhibits' named entity 'human lung' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'inhibits' named entity 'chimeric' named entity 'mice' named entity 'SARS-CoV-2' named entity 'human lung' named entity 'SARS-CoV-2' named entity 'Remdesivir' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'virus' named entity 'anaesthetized' named entity 'prodrug' named entity 'antiviral activity' named entity 'salt' named entity 'receptor' named entity 'Vero E6' named entity 'Vero' named entity 'cell types' named entity 'active form' named entity 'antivirals' named entity 'Fetal' named entity 'antiviral' named entity 'Mice' named entity 'titration' named entity 'exoribonuclease' named entity 'viral replication' named entity 'Vero cell' named entity 'genome' named entity 'endogenous' named entity 'C57Bl/6' named entity 'antiviral activity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software